



Value, Resources, Next Steps, & Adjourment

Daniel Bertges, MD

Misti Malone, FDA


Melanie Raska, Boston Scientific, Inc.



Value



Potential value of registry based studies



Data from Pappas

RAPID ROI

- 6 VQI projects designed and used for regulatory decisions
- ROI greater than 200%



Unpublished data from Cronenwett and Pappas

Next steps

- Submit SPEED OPGs for peer review
- Identify retrospective Phase III project
- Identify prospective Phase IV project supporting regulatory decisions

